QQQ   328.49 (-1.14%)
AAPL   174.55 (+0.88%)
MSFT   291.32 (-0.26%)
META   174.85 (-2.57%)
GOOGL   119.55 (-1.77%)
AMZN   142.10 (-1.85%)
TSLA   911.99 (-0.84%)
NVDA   183.35 (-2.88%)
NIO   20.08 (-3.97%)
BABA   89.77 (-3.11%)
AMD   98.27 (-1.93%)
MU   61.62 (-3.51%)
T   18.42 (-0.81%)
CGC   4.06 (+7.41%)
F   16.03 (-2.43%)
GE   79.92 (-1.42%)
DIS   122.81 (-1.72%)
AMC   21.36 (-13.91%)
PYPL   99.42 (-2.61%)
PFE   49.27 (-1.18%)
NFLX   241.15 (-1.85%)
QQQ   328.49 (-1.14%)
AAPL   174.55 (+0.88%)
MSFT   291.32 (-0.26%)
META   174.85 (-2.57%)
GOOGL   119.55 (-1.77%)
AMZN   142.10 (-1.85%)
TSLA   911.99 (-0.84%)
NVDA   183.35 (-2.88%)
NIO   20.08 (-3.97%)
BABA   89.77 (-3.11%)
AMD   98.27 (-1.93%)
MU   61.62 (-3.51%)
T   18.42 (-0.81%)
CGC   4.06 (+7.41%)
F   16.03 (-2.43%)
GE   79.92 (-1.42%)
DIS   122.81 (-1.72%)
AMC   21.36 (-13.91%)
PYPL   99.42 (-2.61%)
PFE   49.27 (-1.18%)
NFLX   241.15 (-1.85%)
QQQ   328.49 (-1.14%)
AAPL   174.55 (+0.88%)
MSFT   291.32 (-0.26%)
META   174.85 (-2.57%)
GOOGL   119.55 (-1.77%)
AMZN   142.10 (-1.85%)
TSLA   911.99 (-0.84%)
NVDA   183.35 (-2.88%)
NIO   20.08 (-3.97%)
BABA   89.77 (-3.11%)
AMD   98.27 (-1.93%)
MU   61.62 (-3.51%)
T   18.42 (-0.81%)
CGC   4.06 (+7.41%)
F   16.03 (-2.43%)
GE   79.92 (-1.42%)
DIS   122.81 (-1.72%)
AMC   21.36 (-13.91%)
PYPL   99.42 (-2.61%)
PFE   49.27 (-1.18%)
NFLX   241.15 (-1.85%)
QQQ   328.49 (-1.14%)
AAPL   174.55 (+0.88%)
MSFT   291.32 (-0.26%)
META   174.85 (-2.57%)
GOOGL   119.55 (-1.77%)
AMZN   142.10 (-1.85%)
TSLA   911.99 (-0.84%)
NVDA   183.35 (-2.88%)
NIO   20.08 (-3.97%)
BABA   89.77 (-3.11%)
AMD   98.27 (-1.93%)
MU   61.62 (-3.51%)
T   18.42 (-0.81%)
CGC   4.06 (+7.41%)
F   16.03 (-2.43%)
GE   79.92 (-1.42%)
DIS   122.81 (-1.72%)
AMC   21.36 (-13.91%)
PYPL   99.42 (-2.61%)
PFE   49.27 (-1.18%)
NFLX   241.15 (-1.85%)
NASDAQ:BNTX

BioNTech - BNTX Price Target & Analyst Ratings

$152.04
-8.33 (-5.19%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$150.45
$159.14
50-Day Range
$123.25
$183.11
52-Week Range
$117.08
$388.00
Volume
1.12 million shs
Average Volume
1.59 million shs
Market Capitalization
$36.95 billion
P/E Ratio
2.94
Dividend Yield
N/A
Price Target
$235.62

BioNTech Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 14 Analyst Ratings

Consensus Analyst Price Target

$231.43
52.22% Upside
High Prediction$359.00
Average Prediction$231.43
Low Prediction$168.00
TypeCurrent
8/17/21 to 8/17/22
1 Month Ago
7/18/21 to 7/18/22
3 Months Ago
5/19/21 to 5/19/22
1 Year Ago
8/17/20 to 8/17/21
Consensus Rating
Hold
Moderate Buy
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
4 Buy rating(s)
Hold
8 Hold rating(s)
6 Hold rating(s)
7 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$231.43$243.69$263.07$187.50
Predicted Upside52.22% Upside27.47% Upside27.50% Upside-9.49% Downside
Get BioNTech Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter.


BNTX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BNTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BioNTech Stock vs. The Competition

TypeBioNTechMedical CompaniesS&P 500
Consensus Rating Score
2.43
2.70
2.50
Consensus RatingHoldBuyHold
Predicted Upside52.22% Upside881.04% Upside14.53% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
96
46.60%
Underperform Votes
110
53.40%
Avg. Outperform Votes
167
66.80%
Avg. Underperform Votes
83
33.20%
Avg. Outperform Votes
854
68.59%
Avg. Underperform Votes
391
31.41%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/17/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$177.00+10.37%
8/10/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Robert Burns
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy$283.00 ➝ $272.00+70.23%
8/9/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Chris Shibutani
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$200.00+24.57%
8/9/2022Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Zhiqiang Shu
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$312.00+94.33%
8/9/2022Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
William Maughan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$192.00 ➝ $200.00+22.68%
7/29/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Daina Graybosch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform$223.00 ➝ $224.00+35.82%
7/15/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight$195.00 ➝ $194.00+20.58%
7/1/2022Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Emmanuel Papadakis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$180.00+17.49%
6/30/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Eliana Merle
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$168.00+12.68%
5/10/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Cory Kasimov
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$183.00+30.42%
5/9/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Akash Tewari
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$230.00+62.99%
2/1/2022Redburn Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Neutral
12/6/2021Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tazeen Ahmad
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$341.00 ➝ $349.00+9.16%
10/5/2021Bryan, Garnier & Co
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Olga Smolentseva
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$359.00+44.23%
7/19/2021Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$248.00+8.89%
10/29/2020Commerzbank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$119.00+53.47%
(Data available from 8/17/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












BNTX Price Target - Frequently Asked Questions

What is BioNTech's consensus rating and price target?

According to the issued ratings of 14 analysts in the last year, the consensus rating for BioNTech stock is Moderate Buy based on the current 8 hold ratings and 6 buy ratings for BNTX. The average twelve-month price prediction for BioNTech is $231.43 with a high price target of $359.00 and a low price target of $168.00. Learn more on BNTX's analyst rating history.

Do Wall Street analysts like BioNTech more than its competitors?

Analysts like BioNTech less than other Medical companies. The consensus rating for BioNTech is Hold while the average consensus rating for medical companies is Buy. Learn more on how BNTX compares to other companies.

Do MarketBeat users like BioNTech more than its competitors?

MarketBeat users like BioNTech less than other Medical companies. 46.60% of MarketBeat users gave BioNTech an outperform vote while medical companies recieve an average of 66.80% outperform votes by MarketBeat users.

Is BioNTech being upgraded by Wall Street analysts?

Over the previous 90 days, BioNTech's stock had 1 upgrade by analysts.

Does BioNTech's stock price have much upside?

According to analysts, BioNTech's stock has a predicted upside of 26.21% based on their 12-month price targets.


Stock Ratings Reports and Tools

This page (NASDAQ:BNTX) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.